Cryo-Cell International Inc Dossier
|
SectorHealth Care IndustryHealth Care Services Beta (adjusted)0.62 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $4.05Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $32.7M Enterprise Value $40.4M Shares Outstanding 8M diluted Next Earnings Date15 Oct 2026 Last ex-dividend21 May 2025 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Cryo-Cell International is a pioneer in private cord blood banking with a solid recurring revenue base from its processing and storage fees. However, the company is currently facing significant headwinds, including a major legal dispute and arbitration with Duke University over a terminated license agreement. This dispute has paused its high-growth cellular therapy expansion plans (such as the Cryo-Cell Institute for Cellular Therapies and the Celle Corp. spinoff) and led to elevated legal expenses that have severely depressed profitability. Additionally, the company is under a NYSE American continued listing compliance plan through September 9, 2027, due to a stockholders' deficit and recent net losses. While the core storage business remains stable, the stock is a Hold until there is clarity on the Duke arbitration and a clear path to restoring compliance and profitability. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The Duke arbitration results in a complete termination of the license with no recovery of capitalized assets, forcing a permanent write-down. Legal expenses remain high, and the company fails to meet its NYSE American compliance plan, leading to a delisting to the OTC markets and a decline in new specimen enrollments. Base CaseCentral scenario The core cord blood and tissue storage business continues to generate stable, recurring cash flows, but elevated legal fees from the Duke arbitration limit near-term earnings. The company slowly works through its NYSE American compliance plan, maintaining its listing but showing flat to slightly declining revenues due to lower domestic specimen processing. Bull CaseUpside scenario Cryo-Cell's core business model generates highly predictable, recurring revenue from ongoing annual storage fees once families enroll. Additionally, the company has expanded its physical footprint with a 56,000 square foot facility in Durham, NC, which provides capacity for third-party cold storage services (ExtraVault) and potential future cellular therapy manufacturing. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |